Dabigatran performs well in study

01/3/2013 | Healio

The anticoagulant dabigatran performed safely and effectively in a group of 938 unselected patients with atrial fibrillation, according to a German study presented at a meeting. Less than 2% of the patients experienced major cardiovascular events, and 1% experienced minor cardiovascular events. Bleeding complications were experienced by 14.9% of patients, but only 1.5% faced major bleeding, the study found.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC